26 results about "Morphogenesis" patented technology

Disclosed herein are methods for treating a disease or disorder of the central or peripheral nervous system by administering to a subject in thereof an agent capable of modulating the activity or expression of bone morphogenetic protein and activin membrane-bound inhibitor (BAMBI). Additionally, methods for screening agents capable of modulating the activity or expression of BAMBI are disclosed.

Plant cell fate and development is altered by treating cells with cellular reprogramming factors. Embryogenesis inducing embryogenesis factor genes and / or morphogenic developmental genes are used as cellular reprogramming factors, specifically comprising polypeptides or polynucleotides encoding gene products for generating doubled haploids or haploid plants from gametes. Maize microspores treated by contacting the isolated cells with an exogenous purified, recombinant embryogenesis inducing embryogenesis factor gene products and / or morphogenic developmental gene polypeptide results in embryogenesis. The gametes of a maize plant develop into embryoids when transformed with a genetic construct including regulatory elements and structural genes capable of acting in a cascading fashion to alter cellular fate of plant cells. Embryogenesis factor proteins and / or developmental morphogenic proteins expressed from a genetic construct are used for ex situ treatment methods and for in planta cellular reprogramming.

The invention discloses a construction method and application of a cerebellar organoid model, and belongs to the technical field of organoid culture. According to the method, the stability and repeatability of cerebellar organs are remarkably improved by optimizing the components of the culture medium and the induction process. Key morphogenetic factors are regulated and controlled in a stepped mode, and cells are accurately guided to be directionally differentiated to cerebellum; meanwhile, a culture medium without Matrigel is used in the nerve expansion and maturation stages, batch variation of exogenous matrixes is eliminated, and development path consistency and cell composition uniformity are ensured. The organoid constructed on the basis of the method has remarkable advantages in SCA3 disease modeling, single cell sequencing proves that the difference in batches is remarkably smaller than that of an existing method, and a reliable in-vitro human model platform is provided for SCA3 mechanism research and drug screening.

The application provides a bone morphogenetic protein BMP-2 recombinant protein, and the amino acid sequence of the BMP-2 recombinant protein is shown as SEQ ID No. 1. The coding gene, the expression plasmid, the prokaryotic expression vector and the prokaryotic expression method are also disclosed. The prokaryotic expression system is adopted, and a solubilization tag is creatively introduced, so that the inclusion body expression is converted into soluble expression. The BMP-2 is expressed in the form of inclusion body in the prokaryotic system, the protein is converted into soluble expression by adding the solubilization tag, the difficulty of protein separation and purification is reduced, the purification cycle is shortened, and the purification efficiency is improved.

The invention provides a bone repair material and a preparation method and application thereof, the bone repair material is composed of BMP protein (bone morphogenetic protein), carboxymethyl chitosan and calcium chloride, the carboxymethyl chitosan is crosslinked through calcium chloride to form nanoparticles, and the BMP protein is effectively loaded through electrostatic interaction; the bone repair material has good biocompatibility, biosafety and biodegradability, not only can effectively wrap and protect BMP protein from rapid degradation by enzyme, enhance in-vivo stability of BMP protein and realize continuous and controllable release of BMP protein, but also is beneficial to reduction of oedema and ectopic bone risks due to low-dose medication, and has good application prospects. And finally, by promoting angiogenesis, promoting bone tissue development and relieving inflammation, formation and repair of bones are achieved.

The application provides a bone nodule organoid and a preparation method and application thereof, the bone nodule organoid comprises a microsphere carrier system, the microsphere carrier system is made of CGRP, BMP-2, bone marrow mesenchymal stem cells and GelMA-HA-NB hydrogel by a light curing 3D printing technology, the microsphere carrier system is mixed with GelMA hydrogel containing SP to be crosslinked and solidified to form the bone nodule organoid, and the bone nodule organoid is used for in-vivo transplantation to stimulate endogenous bone tissue rapid regeneration;The bone nodule organoid has the ability of two-phase delivery of bioactive factors, different bioactive factors can realize time sequence, differential low dose, slow and continuous release, so that the healing speed and bone repair effect of large-size bone defect are accelerated in a divide-and-rule manner.The application also provides a bioactive factor composition of a bionic bone nodule tissue neurotrophic factor and a physiological dose of bone morphogenetic protein, the composition releases the bone marrow mesenchymal stem cell osteogenic differentiation in the bone nodule organoid according to signal time sequence.

The present application relates generally to the field of bone morphogenetic protein (BMP) antagonists (soluble ALK6 fusion proteins), compositions thereof, and methods for treating degenerative and / or demyelinating diseases of the nervous system.

The application provides a self-development method and system based on a morphogenetic field, and a storage medium. The self-development method comprises the following steps: receiving a user intention, converting the user intention into a structured intention message; generating a functional semantic manifold and a mixed manifold space, and constructing a morphogenetic field; determining an implementation mode of a task target; decomposing the task target into a plurality of design tasks, and determining a design task of each morphogenetic engine; for each local state field, a corresponding morphogenetic engine is used to solve it; determining whether a cooperative stable state is reached among the plurality of morphogenetic engines; after the cooperative stable state is reached, collecting achievement data of the morphogenetic engine, and generating a standardized delivery package. Through intention analysis and construction of a morphogenetic field, the hardware and software implementation mode of the task target is objectively determined, the subjective bias of manual disassembly is eliminated, and the delivery process from abstract intention to standardized engineering products is realized.

The present application relates to the technical field of regenerative medicine application, and particularly relates to a serum-free induction medium with clear components for promoting differentiation of adipose-derived mesenchymal cells into dermal papilla cells, and an induction method and application. A method for promoting differentiation of adipose-derived mesenchymal cells into dermal papilla cells, which is to use a serum-free induction medium to induce culture of adipose-derived mesenchymal cells, so that the adipose-derived mesenchymal cells are differentiated into dermal papilla cells. The formula of the serum-free induction medium comprises hepatocyte growth factor, hydrocortisone, bone morphogenetic protein 2, BIO, and basic fibroblast growth factor. The present application is based on the differentiation potential of adipose-derived mesenchymal cells and the mechanism of maintaining the function of dermal papilla cells, and constructs a serum-free induction system with clear components to realize directional differentiation. The technical scheme can solve the technical problem that there is no method for inducing directional differentiation of adipose-derived mesenchymal cells into dermal papilla cells with effective hair follicle regulation function in the prior art, and has ideal application and popularization potential.

The invention discloses an Anemonium aureum SkORC3 gene as well as an expression protein and application thereof, and belongs to the technical field of plant genetic engineering. The nucleotide sequence of the SkORC3 gene is as shown in SEQ ID NO. 1, and the amino acid sequence of the protein coded by the SkORC3 gene is as shown in SEQ ID NO. 2. According to the invention, the gene is constructed into an overexpression vector and is converted into arabidopsis thaliana, so that the key function of the SkORC3 in regulating and controlling the morphogenesis of plant leaves is disclosed for the first time. A transgenic arabidopsis thaliana plant over-expressing the gene shows remarkable rosette leaf dysplasia, and the specific phenotypes comprise double main vein bifurcated heart-shaped leaves, symmetrical twin leaves at the top end of a petiole, uniaxial special-shaped leaves and the like. The invention provides a new gene resource and tool for molecular mechanism research of plant leaf development, and has potential application value in the field of ornamental plant leaf type molecular breeding.

This invention discloses the application of oxalic acid in the preparation of drugs against Riemerella anatipestifer infection, belonging to the field of biomedical technology. This invention is the first to discover that oxalic acid can inhibit the growth of Riemerella anatipestifer (RA). After treatment with oxalic acid, the bacterial morphology changes significantly, RA biofilm formation is inhibited, and existing biofilms are destroyed. This indicates that oxalic acid can inhibit related virulence phenotypes, exerting an inhibitory effect on the key steps of RA infection—adhesion and colonization—thereby preventing and controlling RA disease. This invention provides a new potential drug for the development of drugs against Riemerella anatipestifer and lays a theoretical foundation.

This invention provides a programmable mechanical metamaterial structure generation method and system based on a reaction-diffusion morphogenesis mechanism. By establishing a reaction-diffusion kinetic model, the structural morphology self-organizes under the coupling effect of local reaction and spatial diffusion, thereby generating structural morphologies with complex topological features and aperiodic spatial distribution characteristics. By setting spatial parameter fields such as diffusion coefficient, supply rate, and disappearance rate within the design domain, and introducing a direction control field to adjust the diffusion direction, the scale characteristics, connectivity, and anisotropy characteristics of the generated structure can be regionalized and continuously controlled. Through threshold transformation, boundary extraction, and geometric reconstruction of the morphology generation results, the generated structure can be directly converted into a two-dimensional or three-dimensional geometric model. This invention expands the design space of mechanical metamaterial structures and realizes an effective connection between structure generation and engineering design and manufacturing.

Aspects of the present disclosure relate to methods and compositions for sugarcane transformation using morphogenic genes. In particular, the present disclosure relates to the use of morphogenic sequences that improve the efficiency of sugarcane cell or tissue transformation and genomic modification. The present disclosure further relates to genetically altered sugarcane cells, tissues, and plants produced using these methods and compositions.

The present invention provides compositions useful for inducing immune responses, treating inflammatory responses, treating microbial infections, cell differentiation, wound healing, embryogenesis, placental development, central nervous system development, or morphogenesis. [Solution] A composition is provided comprising 1) a secretome of about 0.1 w / w% or more, and 2) an excipient acceptable as a pharmaceutical or cosmetic, wherein the secretome comprises MCP-1 and the composition does not contain cells.

Aspects of the present disclosure relate to methods and compositions for sugarcane transformation using morphogenic genes. In particular, the present disclosure relates to the use of morphogenic sequences that improve the efficiency of sugarcane cell or tissue transformation and genomic modification. The present disclosure further relates to genetically altered sugarcane cells, tissues, and plants produced using these methods and compositions.

The application belongs to the technical field of molecular biology breeding, and particularly relates to KcHMR gene or protein and application of the KcHMR gene or protein in improving Arabidopsis thaliana high-temperature stress resistance and a method for cultivating high-temperature resistant Arabidopsis thaliana. The cDNA sequence of the gene is shown as SEQ ID NO. 3; and the amino acid sequence of the protein is shown as SEQ ID NO. 4. The KcHMR gene and the protein thereof provided by the application are beneficial to efficient response of Arabidopsis thaliana to oxidative damage caused by high-temperature stress and rapid adaptation to high-temperature environment through thermal morphogenesis, and the resistance of the Arabidopsis thaliana to high-temperature stress is enhanced. The application provides excellent gene resources for genetic improvement of high-temperature resistant plants and a new idea for obtaining new high-temperature stress resistant plant varieties, and has important theoretical and practical significance for maintaining growth and development of plants and improving yield of economic crops under the condition of climate warming.

This application discloses a method for monitoring and assessing the replication of Wenzhou-related virus (WZRV) infection based on mouse lung and / or kidney organoids. The method includes: obtaining lung and / or kidney organoids from SD rats; infecting the organoids with WZRV; culturing the infected organoids; and collecting samples at different time points after infection for viral replication and tissue tropism analysis. This application establishes a standardized lung / kidney organoid model from SD rats and, combined with multi-dimensional detection methods such as RT-qPCR nucleic acid quantification, infectivity titer determination, immunofluorescence co-localization, and transmission electron microscopy, can systematically assess viral replication kinetics, tissue / cell tropism, and morphogenesis characteristics. This application constructs a reproducible and comparable standardized assessment system that realistically reflects the replication behavior and target cell preference of WZRV under near-physiological conditions, providing a reliable in vitro platform for viral pathogenesis research and antiviral drug screening.

Disclosed are methods of treating musculoskeletal and / or bone diseases using at least one inhibitor of bone morphogenic protein (BMP) / transforming growth factor-beta (TGF-β) signaling and at least one activator of Hedgehog (Hh) signaling.

The present application provides a method for producing seaweed cells, which comprises: (A) culturing at least one selected from spores of seaweed, single cells derived from the spores, and cell aggregates of the spores and / or the single cells in a medium 1 substantially free of seaweed morphogenesis inducers under stirring.

The invention discloses a chemical small molecule composition for inducing directional differentiation of umbilical cord mesenchymal stem cells into dopaminergic neurons, a culture medium, an induction method and application. The chemical small molecule composition is prepared from SB431542, LDN193189, CHIR99021, Forskolin, Y27632, FGF8 (Fibroblast Growth Factor 8), SHH (Secret Hormone Hormone) and DAPT (Diaminopropyltriethoxysilane). A chemical reprogramming method without gene integration is established through combination of small molecule compounds and morphogenetic factors, human umbilical cord mesenchymal stem cells are efficiently induced and differentiated into dopaminergic neurons, and a safe, stable and clinically convertible functional cell source is provided for cell replacement treatment of Parkinson's disease. According to the scheme, the problems of tumorigenicity, ethical limitation, immunological rejection and the like in a traditional induction method are solved, and a new technical path and a new cell preparation strategy are provided for stem cell treatment of neurodegenerative diseases.

Provided in the present invention is an oligosaccharide-based multifunctional plant immunomodulator. Specifically, the plant immunomodulator has a structure represented by formula I below. The plant immunomodulator of the present invention can not only regulate the growth and development of crops, but also induce crops to resist against biological stress and abiotic stress, thereby improving the yield and quality of crops. By using the plant immunomodulator of the present invention, not only can multiple plant growth and development processes be positively regulated, including promoting seed germination, seedling morphogenesis and plant vigor at the mature stage, thereby increasing the crop yield and fruit quality, but also improving the resistance of plants against biological stress (diseases, insects and weeds) and abiotic stress (a frozen or near-frozen soil environment, drought, waterlogging, salinity and alkalinity, extremely low / high temperature, etc.). In addition, the plant immunomodulator of the present invention has the advantages of being non-toxic, free of pesticide residues, environmentally friendly, incapable of inducing pesticide resistance in pathogens, etc.

To provide a new method for producing mesoderm-derived vascular progenitor cells by in vitro differentiation of pluripotent stem cells. Further provided are methods of treating vascular disease, e.g., critical limb ischemia.SOLUTION: A method for producing a population of mesodermal-derived vascular progenitor cells (meso-VPCs) from pluripotent stem cells, comprising culturing pluripotent stem cell-derived mesodermal cells under non-adherent or low-adherent conditions in a medium comprising one or more factors selected from the group consisting of vascular endothelial growth factors (VEGFs), fibroblast growth factors (FGFs), bone morphogenetic protein-4 (BMP4), and small-molecule inhibitors of transforming growth factor-beta (TGF - β) type I receptor, thereby producing a population of mesodermal-derived vascular progenitor cells. The method includes: SELECTED DRAWING: Figure 3

Provided is a method for culturing a sample of cells, which includes circulating epithelial cells, peripheral blood mononuclear cells (PBMC), or body fluid-derived cell samples (e.g. blood, ascites, pleural effusions, cerebrospinal fluids, perfusion fluids, sputum, and urine), or liquid biopsyderived cell samples in presence of Bone Morphogentic Protein (BMP) inhibitor, a mitogenic growth factor, and a Wnt agonist, when culturing the circulating epithelial cells and relevant blood cells. Also provided is use of cell medium having a BMP inhibitor, a mitogenic growth factor, and a Wnt agonist in obtaining a cell culture of circulating epithelial cells, PBMC and body fluid-derived cells.

The invention relates to the technical field of biomedicine, and discloses an induction combined culture medium and application thereof, and a method for inducing pluripotent stem cells to directionally differentiate into precursor cells of osteogenesis, cartilage and matrix. The induction combined culture medium comprises an induction culture medium I and an induction culture medium II; the induction culture medium I is prepared from a StemFit Basic 03 basic culture medium, an induction factor SB431542 and an induction factor CHIR99021; the induction culture medium II comprises an alpha MEM basal culture medium, a platelet lysate, an induction factor SB431542, an induction factor CHIR99021, a bone morphogenetic protein BMP2, dexamethasone and ascorbic acid 2-phosphate; in the induction culture medium I and the induction culture medium II, the concentration of the induction factor CHIR99021 is respectively and independently 2 mu M to 4 mu M. The method can provide standardized clinical-grade functional precursor cells capable of being prepared on a large scale for cell therapy of bone-related diseases, effectively solves the bottlenecks of low differentiation efficiency, insufficient purity and poor stability in the prior art, and provides key cell resource support for clinical transformation in the direction of bone repair in regenerative medicine.